Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Clinical trial NCT06809530 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06809530
Sponsor: Guangzhou Medical University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leptomeningeal Metastasis Pemetrexed PD-1 Inhibitor CTLA4 Solid Tumors

Start date: 2025-03-17
Primary completion: 2026-12-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.